CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
We break down Nobl SDY fees, showing which charges eat into profits and how to minimize them through smarter selection and timing of trades.
20,285 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Snowflake and MongoDB posted solid Q1 results, stoking debate on which cloud data platform is the mongodb snowflake: ...
The AI boom relies on more than chips. It hinges on the invisible backbone—equipment that enables chipmakers to scale...
As America reshapes its manufacturing landscape, rare earths play a pivotal role in magnets, EVs, and wind turbines. ...
If you are weighing where to invest in the chip sector, this article breaks down how Intel and TSMC differ, what that...
A landmark portfolio reshuffle puts Alphabet ahead of Berkshire's long-time Coca-Cola cornerstone. This analysis expl...
SanDisk and Micron trade on different business models in a volatile memory cycle. The next moves hinge on manufacturi...
Taiwan Semiconductor Manufacturing Co. reports a 36% quarterly sales increase, with June revenue surging as memory eq...
Japan cleared a landmark crypto regime today, moving oversight under the Financial Instruments and Exchange Act and d...
CoreWeave is expanding fast on the AI cloud frontier, but heavy borrowing and rising interest expenses are pulling th...
Bank earnings just dropped fresh clues about how Americans are spending, borrowing, and saving. This deep dive breaks...
A delayed earnings release and a premium acquisition sparked a slide in Valaris shares. This article breaks down what...